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Dear Editor,
Here we describe a patient with intractable epilepsy and post-
ictal psychosis, successfully treated with adjunctive ethosuximide.
X is a 37-year-old gentleman (weight 104 kg) with cryptogenic
localization-related epilepsy and post-ictal psychosis. He ﬁrst
developed epilepsy after sustaining a head injury as a teenager;
this led to regular and persistent complex partial seizures despite
different combinations of anti-epileptic and psychotropic medica-
tion (including topiramate; levetiracetam; carbamazepine; phe-
nytoin; haloperidol; clobazam; diazepam; risperidone; and
pregabalin) as well as tertiary specialist input.
Psychiatric symptoms in X developed four years agowhen, in an
attempt to treat his epilepsy, a person claiming to be an Ayurvedic
practitioner (whom was subsequently arrested) prescribed what
was believed to be a herbalmedication in place of X’s anti-epileptic
medication. The new medication on subsequent analysis was
found to contain a mixture of carbamazepine, phenobarbitone,
phenytoin, and a number of other drugs including neuroleptics;
one of which has previously been licensed for animal-use and is
now banned. Unfortunately, the epilepsy persisted with the added
complication of post-ictal psychosis. Understandably, this led to a
loss of self-conﬁdence in X as his social and functional performance
declined.
X initially experienced tonic–clonic convulsions alone; how-
ever, over the last year these have evolved into absence (petit mal)
episodes occurring at least twice-weekly. During each episode X
would appear vacant and detached for several minutes; this is
followed by several hours of threatening behaviour, characterized
by paranoid and grandiose delusions. After each episode, X would
fall into a deep sleep then awake with little recollection of the
event. This occurred despite treatment with carbamazepine-MR
1000 mg OD; phenytoin 150 mg mane´, 200 mg nocte´; topiramate
200 mg BD; risperidone 4 mg mane´, 5 mg nocte´; and lorazepam
1 mg BD, 2 mg BD, concurrently. Investigations at this time
revealed an EEG report that frontal regions featured an arrhythmic
delta slow wave activity admixed to the ongoing rhythms,
explicable in terms of anti-epileptic medication and psychotropic
medication. In addition, sharp wave discharges, which featured,
were lateralised to the left hemisphere ﬁeld being inferior frontal/
anterior temporal. Secondly, a CT brain scan showed no signiﬁcant
asymmetry, anomaly nor abnormality of the intracranial content
with no evidence of any intracranial haemorrhage or haematoma:
an essentially normal report.
Two months prior to writing, a trial of adjunctive ethosuximide
was begun which immediately produced a favourable result; this1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.08.006involved the introduction of ethosuximide at 500 mg daily
followed by an increase to 500 mg BD, over a 2-week period.
Since its commencement, X has remained seizure- and psychosis-
free apart from one brief episode triggered by extreme stress. This
has facilitated an improvement in both his psycho-social
performance and in his self-esteem.
Psychosis following seizure activity is well-established in the
medical literature. Esquirol described post-ictal ‘‘fury’’ lasting from
hours to days in his textbook of psychiatry (1838)4; andHughlings-
Jackson reported ‘‘acute attacks of insanity (epileptic mania)’’ in
patients.1 The typical patient appears psychiatrically well until a
cluster of tonic–clonic seizures, with or without complex partial
seizures, occurs. After an initial post-ictal period marked by
confusion and lethargy, the patient improves for hours to days (the
lucid interval). Following this, psychosis develops and typically
lasts days to weeks.2 X is atypical in that his psychosis appears
immediately after each absence episode and lasts for no more than
a few hours.
Ethosuximide is the drug of choice for the control of seizures in
absence epilepsy. However, psychiatric side effects, particularly in
those with a history of mental health problems, have limited its
use. These have included sleep disturbances, poor concentration,
aggressiveness and, rarely, depression and paranoid psychosis.3
Nonetheless, we suggest that ethosuximidemay have a place as an
adjunctive treatment for resistant post-ictal psychosis where
breakthrough absence seizures predominate.
References
[1] Taylor J. Selected writings of John Hughlings Jackson. New York: Basic Books;
1958.
[2] Devinsky O. Postictal psychosis: common, dangerous, and treatable. Epilepsy
Curr 2008;8(2):31–4.
[3] Go¨ren M, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev
2007;13(2):224–39.
[4] Esquirol E. Des maladies mentales considere´es sous les rapports me´dical. Paris,
Ballie`re: Hygienique et Me´dico-Legal; 1838.
Apu T. Chakraborty*
Ibrahim Youssef
Weymouth & Portland Community Mental Health Team,
Radipole Lane, Weymouth, Dorset DT4 0QE, United Kingdom
*Corresponding author. Tel.: +44 1305 362 052
E-mail address: apu.chakraborty@dorset-pct.nhs.uk
(A.T. Chakraborty)
2 July 2007vier Ltd. All rights reserved.
